Introducing a New Antifungal Surveillance Program: Analysis of Resistance to Antifungals (ARIA) and Expanded Mycology Services at IHMA
International Health Management Associates (IHMA) has initiated a new antifungal resistance surveillance program, Analysis of Resistance to Antifungals (ARIA) to further the development of new antifungal agents and monitor the development of antifungal resistance.
ARIA collects and determines the antifungal susceptibility of clinically-relevant Candida spp., which includes the emerging C. auris, filamentous fungi, and also rarer molds from hospitals world-wide, including China and India. IHMA offers an option for biopharmaceutical companies to add new antifungal agents to the program.
The first presentation of ARIA data - Analysis of Resistance In Antifungals (ARIA) - Global Surveillance of Candida spp. Isolates, Including C. auris, in 2019 - will be made at the upcoming 10th Trends in Medical Mycology (TIMM-10), 8-11 October 2021, Aberdeen, Scotland.
The ARIA program greatly enhances IHMA's pre-clinical and clinical mycology capabilities at the European facility (Monthey, Switzerland) to profile new products, molecularly characterize antifungal resistance mechanisms, and serve as a central laboratory for clinical trials.
“IHMA is continuously looking for new ways to help clients progress with their new anti-infective agent programs. Our ability to adapt and add new capabilities shows our flexibility, dedication, and interest in assisting clients in the ongoing fight against antimicrobial resistance. The addition of mycology services augments our goal to support the biopharmaceutical industry by providing a suite of premier microbiology services to clients wishing to conduct antifungal studies on a global scale,” said Jack L. Johnson, President/CEO of IHMA.
About IHMA:
As the leading global microbiology service provider to the biopharmaceutical industry, IHMA utilizes its extensive laboratory and industry expertise to support efficient and effective anti-infective product development. IHMA is a premier provider of reference laboratory services to support anti-infective product discovery and development as well as the development of diagnostic devices that detect bacterial resistance to antimicrobial agents and new technologies as they emerge.
For more information, please visit IHMA’s website (www.ihma.com).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005044/en/
Contact information
Darcie Carpenter PhD CIC
Director Global Business Development
+1.530.577.5296
dcarpenter@ihma.com
Ian Morrissey MBA PhD FRSM
Chief Scientific & Development Officer
+44.01279.724929
imorrissey@ihma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coats Completes Acquisition of OrthoLite, Strengthening Footwear Business30.10.2025 09:15:00 EET | Press release
Coats Group plc, a world-leading Tier 2 supplier of critical components to the apparel and footwear industries, announced today that it has completed its acquisition of OrthoLite, a global market leader in footwear materials and the number one brand in premium insoles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030015142/en/ OrthoLite Vietnam The acquisition marks a major milestone in the Company’s long-term growth plans and strengthens its existing footwear division through expansion into the attractive, high-growth premium insole segment. Both companies already have a similar customer base, a complementary global footprint and a commitment to industry-leading innovation and sustainability practices. “OrthoLite is one of the world’s most innovative manufacturers in footwear materials. With our combined capabilities, we’ll now be able to offer our customers more future-focused solutions for more of the shoe – without
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year30.10.2025 09:04:00 EET | Press release
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: “Takeda’s fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of transition to a new phase focusing on new product launches. Our updated full-year outlook reflects impairment charges associated with strategic pipeline decisions taken in Q2, as well as transactional FX. “Looking ahead, our current Growth and Launch Products portfolio will continue to generate moderate growth, which will accelerate in the future with new launches. We see FY2025 as a pivotal year for Takeda with regulatory filings for rusfertide and oveporexton expected in the second half of the year, as well as Phase 3 results for zasocitinib. We continue to expand our external partnerships to enhance the depth and breadth of our R&D pi
AGCO Power Unveils Next-Generation Sustainable Powertrain Innovations at Agritechnica 202530.10.2025 09:00:00 EET | Press release
At Agritechnica 2025 in Hanover, AGCO Power will unveil a bold vision for the future of agricultural and forestry machinery powertrain solutions—combining cutting-edge diesel technology with pioneering low-carbon innovations designed to meet the evolving needs of farmers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030745855/en/ Juha Heikkilä (left), Manager Electrification, holds NMC battery cells used in the prototype battery, while Kari Aaltonen, Director Engineering, stands beside the concept unit. The battery, designed by AGCO Power, contains a total of 1400 cells and offers 150 kWh of capacity. Highlights include the newest and next‑generation CORE diesel engine family—the 8‑liter, 252 kW CORE80 powering the new 5th‑generation of the Fendt 800 Vario—alongside the AGCO Power CO₂ Calculator concept and a 150 kWh Future Battery Concept developed in‑house by AGCO Power, and cost-effective remanufactured eng
Aduna, Deutsche Telekom, mBank and Vonage Join Forces at World Banking Forum to Showcase the Future of Banking Security30.10.2025 09:00:00 EET | Press release
Vonage, a part of Ericsson (NASDAQ: ERIC), today announced that, together with leaders from Aduna, Deutsche Telekom, and mBank, it is participating in the World Banking Forum in Athens. The event convenes senior banking executives and technology leaders from around the world to advance modern banking through technology innovation and digital transformation. An increase in fraud has emerged from the rise of digital channels in financial services and continues to evolve and grow with new technologies such as AI that enable more sophisticated threats. As cyber threats continue to escalate and regulations tighten, it is more critical than ever for banks to deploy advanced fraud protection strategies. Cybercrime damages are projected to reach $11.9 trillion annually by 2026 and technology innovation is needed to meet regulatory demands and strengthen a financial institution's overall fraud defenses.1 At the World Banking Forum, Aduna, Deutsche Telekom, mBank, and Vonage will explore how the
AB InBev Reports Third Quarter 2025 Results30.10.2025 08:05:00 EET | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029571716/en/ Regulated and inside information1 “Driven by the momentum of our megabrands and our innovation in balanced choices and Beyond Beer, our business delivered continued top- and bottom-line growth, even as we navigated a dynamic consumer environment. Given the progress we have made on our deleveraging and solid year-to-date financial results we have announced a new 6 billion USD share buyback program and an interim dividend.” – Michel Doukeris, CEO, AB InBev Revenue +0.9% Revenue increased by 0.9% in 3Q25 with revenue per hl growth of 4.8% and by 1.8% in 9M25 with revenue per hl growth of 4.5%. Reported revenue increased by 0.6% in 3Q25 to 15 133 million USD and decreased by 2.6% in 9M25 to 43 764 million USD, impacted by unfavorable currency translation. 3.0% increase in combined revenues of megabra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom